Vimarsana
Biggest News Aggregation in the World

Page 3 - Colitis Center News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Colitis Center. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Colitis Center Today - Breaking & Trending Today

First Phase 3 TREMFYA® (guselkumab) Data in Inflammatory Bowel Disease Show Positive Induction Results Among Patients with Moderately to Severely Active Ulcerative Colitis - Vimarsana News

First Phase 3 TREMFYA® (guselkumab) Data in Inflammatory Bowel Disease Show Positive Induction Results Among Patients with Moderately to Severely Active Ulcerative Colitis

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new efficacy and safety data from the Phase 3 QUASAR Induction Study...

Johnson & Johnson : First Phase 3 TREMFYA® (guselkumab) Data in Inflammatory Bowel Disease Show Positive Induction Results Among Patients with Moderately to Severely Active Ulcerative Colitis - Vimarsana News

Johnson & Johnson : First Phase 3 TREMFYA® (guselkumab) Data in Inflammatory Bowel Disease Show Positive Induction Results Among Patients with Moderately to Severely Active Ulcerative Colitis

That cause chronic inflammation of the gastrointestinal tract.6 Prolonged inflammation results in damage to the GI tract.6 The exact cause of IBD is unknown but may be the result of the immune... | May 9, 2023

FMT in a Pill: FDA OKs Second Product to Prevent Recurrent C difficile - Vimarsana News

FMT in a Pill: FDA OKs Second Product to Prevent Recurrent C difficile

Clinicians now have two approved options for recurrent infections after antibiotic treatment.

Dr Jessica Allegretti: Major Advancements Being Explored for Prevention, Treatment of CDI - Vimarsana News

Dr Jessica Allegretti: Major Advancements Being Explored for Prevention, Treatment of CDI

Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital, reviews emerging therapeutics being investigated for the prevention and treatment of Clostridioides difficile infection (CDI).

Source: ajmc.com
Dr Jessica Allegretti Addresses Rebyota Utilization, Access Considerations for Recurrent CDI - Vimarsana News

Dr Jessica Allegretti Addresses Rebyota Utilization, Access Considerations for Recurrent CDI

Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital, speaks on current indications for Rebyota (fecal microbiota, live-jslm) in the treatment of recurrent Clostridioides difficile infection (CDI), as well as coverage and access-related implications for the drug.

Source: ajmc.com